We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Transfusion and Treatment of severe anaemia in African children (TRACT): a study protocol for a randomised controlled trial.
- Authors
Mpoya, Ayub; Kiguli, Sarah; Olupot-Olupot, Peter; Opoka, Robert O.; Engoru, Charles; Mallewa, Macpherson; Chimalizeni, Yami; Kennedy, Neil; Kyeyune, Dorothy; Wabwire, Benjamin; M'baya, Bridon; Bates, Imelda; Urban, Britta; von Hensbroek, Michael Boele; Heyderman, Robert; Thomason, Margaret J.; Uyoga, Sophie; Williams, Thomas N.; Gibb, Diana M.; George, Elizabeth C.
- Abstract
<bold>Background: </bold>In sub-Saharan Africa, where infectious diseases and nutritional deficiencies are common, severe anaemia is a common cause of paediatric hospital admission, yet the evidence to support current treatment recommendations is limited. To avert overuse of blood products, the World Health Organisation advocates a conservative transfusion policy and recommends iron, folate and anti-helminthics at discharge. Outcomes are unsatisfactory with high rates of in-hospital mortality (9-10%), 6-month mortality and relapse (6%). A definitive trial to establish best transfusion and treatment strategies to prevent both early and delayed mortality and relapse is warranted.<bold>Methods/design: </bold>TRACT is a multicentre randomised controlled trial of 3954 children aged 2 months to 12 years admitted to hospital with severe anaemia (haemoglobin < 6 g/dl). Children will be enrolled over 2 years in 4 centres in Uganda and Malawi and followed for 6 months. The trial will simultaneously evaluate (in a factorial trial with a 3 x 2 x 2 design) 3 ways to reduce short-term and longer-term mortality and morbidity following admission to hospital with severe anaemia in African children. The trial will compare: (i) R1: liberal transfusion (30 ml/kg whole blood) versus conservative transfusion (20 ml/kg) versus no transfusion (control). The control is only for children with uncomplicated severe anaemia (haemoglobin 4-6 g/dl); (ii) R2: post-discharge multi-vitamin multi-mineral supplementation (including folate and iron) versus routine care (folate and iron) for 3 months; (iii) R3: post-discharge cotrimoxazole prophylaxis for 3 months versus no prophylaxis. All randomisations are open. Enrolment to the trial started September 2014 and is currently ongoing. Primary outcome is cumulative mortality to 4 weeks for the transfusion strategy comparisons, and to 6 months for the nutritional support/antibiotic prophylaxis comparisons. Secondary outcomes include mortality, morbidity (haematological correction, nutritional and infectious), safety and cost-effectiveness.<bold>Discussion: </bold>If confirmed by the trial, a cheap and widely available 'bundle' of effective interventions, directed at immediate and downstream consequences of severe anaemia, could lead to substantial reductions in mortality in a substantial number of African children hospitalised with severe anaemia every year, if widely implemented.<bold>Trial Registration: </bold>Current Controlled Trials ISRCTN84086586 , Approved 11 February 2013.
- Subjects
AFRICA; MALAWI; UGANDA; ANEMIA in children; CHILDREN; RANDOMIZED controlled trials; MALARIA; ANTIBIOTIC prophylaxis; SEPSIS; MICRONUTRIENTS; HEMOGLOBINS; ANEMIA diagnosis; ANEMIA treatment; AGE distribution; ANEMIA; ANTHELMINTICS; BLOOD transfusion; CHILD mortality; DIETARY supplements; DRUG administration; EXPERIMENTAL design; HEALTH status indicators; HOSPITAL admission &; discharge; INFANT mortality; RESEARCH protocols; PATIENTS; RESEARCH funding; TIME; VITAMINS; DISEASE relapse; TREATMENT effectiveness; SEVERITY of illness index; HOSPITAL mortality; NUTRITIONAL status
- Publication
Trials, 2015, Vol 16, Issue 1, p1
- ISSN
1745-6215
- Publication type
journal article
- DOI
10.1186/s13063-015-1112-4